<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32862509</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Does including machine learning predictions in ALS clinical trial analysis improve statistical power?</ArticleTitle><Pagination><StartPage>1756</StartPage><EndPage>1765</EndPage><MedlinePgn>1756-1765</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51140</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which leads to progressive muscle weakness and eventually death. The increasing availability of large ALS clinical trial datasets have generated much interest in developing predictive models for disease progression. However, the utility of predictive modeling on clinical trial analysis has not been thoroughly evaluated.</AbstractText><AbstractText Label="METHODS">We evaluated a predictive modeling approach for ALS disease progression measured by ALSFRS-R using the PRO-ACT database and validated our findings in a novel test set from a former clinical trial. We examined clinical trial scenarios where model predictions could improve statistical power for detecting treatment effects with simulated clinical trials.</AbstractText><AbstractText Label="RESULTS">Models constructed with imputed PRO-ACT data have better external validation results than those fitted with complete observations. When fitted with imputed data, super learner (R<sup>2</sup> &#xa0;=&#xa0;0.71, MSPE&#xa0;=&#xa0;19.7) and random forest (R<sup>2</sup> &#xa0;=&#xa0;0.70, MSPE&#xa0;=&#xa0;19.6) have similar performance in the external validation and slightly outperform the linear mixed effects model (R<sup>2</sup> &#xa0;=&#xa0;0.69, MSPE&#xa0;=&#xa0;20.5). Simulation studies suggest including machine learning predictions as a covariate in the analysis model of a 12-month clinical study can increase the trial's effective sample size by 16% when there is a hypothetical treatment effect of 25% reduction in ALSFRS-R mean rate of change.</AbstractText><AbstractText Label="INTERPRETATION">Predictive modeling approaches for ALSFRS-R are able to explain a moderate amount of variability in longitudinal change, which is improved by robust missing data handling for baseline characteristics. Including ALSFRS-R post-baseline model prediction results as a covariate in the model for primary analysis may increase power under moderate treatment effects.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manser</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9332-0975</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>N.Z.: Paid intern at Genentech, Inc. and current graduate student at the University of Michigan. P.M.: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32862509</ArticleId><ArticleId IdType="pmc">PMC7545604</ArticleId><ArticleId IdType="doi">10.1002/acn3.51140</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, et al. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol 2019;16:505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 2014;10:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RP, Westeneng HJ, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 2019;92:451&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Taylor AA, Beaulieu D, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol 2018;5:474&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899911</ArticleId><ArticleId IdType="pubmed">29687024</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, Fournier C, Polak M, et al. Predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2016;3:866&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateralsclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. The PRO&#x2010;ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zach N, Ennist DL, Taylor AA, et al. Being PRO&#x2010;ACTive: what can a clinical trial database reveal about ALS? Neurotherapeutics 2015;12:417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404433</ArticleId><ArticleId IdType="pubmed">25613183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II&#x2212;III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 2014;2:529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RJA. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc 1988;83:1198&#x2013;1202.</Citation></Reference><Reference><Citation>Stekhoven DJ, B&#xfc;hlmann P. MissForest&#x2014;non&#x2010;parametric missing value imputation for mixed&#x2010;type data. Bioinformatics 2011;28:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">22039212</ArticleId></ArticleIdList></Reference><Reference><Citation>Waljee AK, Mukherjee A, Singal AG, et al. Comparison of imputation methods for missing laboratory data in medicine. BMJ Open 2013;3:e002847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733317</ArticleId><ArticleId IdType="pubmed">23906948</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L. Random forests. Mach Learn 2011;45:5&#x2013;32.</Citation></Reference><Reference><Citation>van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol 2007;6:article25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17910531</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro J, Bates D. Mixed&#x2010;effects models in S and S&#x2010;PLUS, statistics and computing. New York: Springer&#x2010;Verlag, 2000.</Citation></Reference><Reference><Citation>Sela RJ, Simonoff JS. RE&#x2010;EM trees: a data mining approach for longitudinal and clustered data. Mach Learn 2012;86:169&#x2013;207.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>